MedTrace Logo

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

NCT06648525 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2024-10-18

No results posted yet for this study

Summary

This is a multicenter, open label, randomized, two-arm clinical study to observe and evaluate the efficacy and safety of adebrelimab combined with irinotecan liposomes, 5-fluorouracil, calcium folinate ± lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma (ICC).

Conditions

  • Intrahepatic Cholangiocarcinoma (Icc)

Interventions

DRUG

Adebrelimab

Adebrelimab, IV

DRUG

Irinotecan liposomes

Irinotecan liposomes, IV

DRUG

Lenvatinib

Lenvatinib, po

DRUG

5-Fluorouracil (5-FU)

5-Fluorouracil (5-FU), IV

DRUG

Calcium Folinate

Calcium folinate, IV

Sponsors & Collaborators

  • Harbin Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-31
Primary Completion
2027-04-30
Completion
2028-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06648525 on ClinicalTrials.gov